Investigating how sphingolipids affect non-small cell lung cancer driven by KRAS mutations
Official title: BCCMA: The Role of Sphingolipids in the Induction & Maintenance of Non-Small Cell Lung Cancer by Oncogenic KRAS
Funded at VA Veterans Administration Hospital · NIH-10951489 · Data updated 2026-11-12
This study is looking at how certain fats in the body, called sphingolipids, might affect the growth of non-small cell lung cancer, especially when a specific gene is mutated, to find new ways to treat patients with this tough type of cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Veterans Administration Hospital NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project start | October 1, 2023 |
| Project end | September 30, 2027 |
| Funding year | 2025 |
| NIH project number | 5I01BX006063-02 |
| Project ID | NIH-10951489 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer, particularly those with KRAS mutations.
✕Less likely to help
Patients with other types of lung cancer or those without KRAS mutations may not benefit from this research.
What this research studies
This research focuses on understanding the role of sphingolipids in the development and maintenance of non-small cell lung cancer (NSCLC), particularly in cases where the KRAS gene is mutated. The team aims to identify specific changes in sphingolipid metabolism that occur during the formation of cancer cells, which could lead to new therapeutic strategies. By using advanced techniques to analyze these metabolic pathways, the research seeks to translate findings from laboratory models to human NSCLC cases. Ultimately, the goal is to explore whether targeting sphingolipid pathways can provide new treatment options for patients with this aggressive form of cancer.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve outcomes for patients with non-small cell lung cancer.
How similar studies have gone: While the role of sphingolipids in cancer is an emerging field, similar research has shown promise in understanding cancer metabolism and developing targeted therapies.
Where this research is happening
-
VA Veterans Administration Hospital
Richmond, United States Active
Researchers
- Principal investigator: Chalfant, Charles E. — VA Veterans Administration Hospital
- Study coordinator: Chalfant, Charles E.
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.